Lilly’s Prasugrel No Match For Clots Compared To Plavix, Bristol Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In contrast to Lilly, Bristol management says it expects FDA to schedule an advisory committee review for the Plavix competitor.